To conduct a long-term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV). RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis / De Vita S; Quartuccio L; Isola M; Mazzaro C; Scaini P; Lenzi M; Campanini M; Naclerio C; Tavoni A; Pietrogrande M; Ferri C; Mascia MT; Masolini P; Zabotti A; Maset M; Roccatello D; Zignego AL; Pioltelli P; Gabrielli A; Filippini D; Perrella O; Migliaresi S; Galli M; Bombardieri S; Monti G.. - In: ARTHRITIS AND RHEUMATISM. - ISSN 0004-3591. - STAMPA. - 64:(2012), pp. 843-853.
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis.
LENZI, MARCO;
2012
Abstract
To conduct a long-term, prospective, randomized controlled trial evaluating rituximab (RTX) therapy for severe mixed cryoglobulinemia or cryoglobulinemic vasculitis (CV). RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
